Summary: <br> <a href="https://twitter.com/intent/tweet?url=http%3A%2F%2Fwww.talkingbiotechpodcast.com%2F258-rapid-detection-of-bloodborne-pathogens%2F&via=talkingbiotech" class="twitter-share-button" data-size="large">Tweet</a><br> <a href="https://i0.wp.com/www.talkingbiotechpodcast.com/wp-content/uploads/2020/09/258-helixbind.jpg"></a><br> Sepsis is an infection of the blood. It can be critical and life threatening, and can complicate other co-morbidities. One of the main problems is that a number of bacterial and fungal pathogens can cause a septic state, so physicians are tasked with rapid identification of specific pathogens to render the most appropriate method of care. Unfortunately this usually involves broad treatments with multiple antibiotics and antifungals, as tests to identify discrete pathogens can take days. Dr. Alon Singer is the CEO of Helixbind. They have developed a new technology that allows rapid detection of bloodborne pathogens, eclipsing many of the barriers that previously led to longer detection times and greater patient risk.<br> More information at www.helixbind.com<br> <br>
